Agenus receives fast track designation for balstilimab & zalifrelimab in advanced cervical cancer

Agenus receives fast track designation for balstilimab & zalifrelimab in advanced cervical cancer.agenus inc - expects to file 2 blas this year for accelerated approval of combination of balstilimab and zalifrelimab and balstilimab monotherapy.

AGEN Ratings Summary

AGEN Quant Ranking